REG - Solvonis Therapeutic - Granted U.S. Patent from PTSD Discovery Programme

Solvonis TherapeuticsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260408:nRSH5132Za&default-theme=true

RNS Number : 5132Z  Solvonis Therapeutics PLC  08 April 2026

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM
BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF
THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE
INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

8 April 2026

 

Solvonis Therapeutics plc

("Solvonis" or the "Company")

 

Granted Second U.S. Patent from PTSD Discovery Programme

 

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company
developing novel small-molecule therapeutics for high-burden central nervous
system ("CNS") disorders, announces that it has been granted a second U.S.
patent by the United States Patent and Trademark Office ("USPTO") covering a
further monoamine modulator compound series arising from its proprietary
post-traumatic stress disorder ("PTSD") discovery programme.

The patent, U.S. Patent No. 12,595,269, was issued on 7 April 2026 and covers
a chemically distinct monoamine modulator series designed to modulate
serotonin, dopamine and noradrenaline transporter systems (SERT, DAT and NET).
The patent term is expected to run until 16 February 2043, subject to
maintenance fee payments and any applicable extensions or adjustments.

PTSD is a large and underserved market affecting more than 20 million people
across the UK, U.S. and major European markets, with limited approved
pharmacological treatment options. Recent strategic activity in the sector,
including Otsuka Pharmaceutical Co., Ltd.'s ("Otsuka") agreement to acquire
Transcend Therapeutics for total potential consideration of US$1.225 billion,
reflects increasing focus by pharmaceutical companies on next-generation
psychiatric treatments targeting core monoamine pathways.

This patent is a composition-of-matter patent, meaning it protects the
compounds themselves rather than only specific uses or methods of manufacture.
In pharmaceutical development, this form of protection is generally regarded
as the most robust and commercially valuable, as it secures exclusive rights
to the underlying molecules.

 

This second granted patent builds on a series of recent milestones across
Solvonis' PTSD discovery programme, including the USPTO Notice of Allowance
announced in January 2026, the selection of SVN-114 as lead candidate in March
2026, and the grant of U.S. Patent No. 12,590,077 on 31 March 2026. Together,
these milestones continue to strengthen and expand the Company's protected
chemistry estate in PTSD.

 

Importantly, the grant of two U.S. patents across two chemically distinct
monoamine modulator series reinforces the breadth of the Company's research
platform and supports future optimisation, lifecycle management and follow-on
development opportunities beyond a single lead asset.

 

Professor David Nutt, Chief Scientific Officer of Solvonis Therapeutics plc,
commented: "This second patent reflects the breadth of our monoamine
modulation research and the scientific strategy behind it. By exploring
multiple chemically distinct series acting across SERT, DAT and NET, we
increase the probability of identifying differentiated compounds with
attractive translational and therapeutic profiles."

 

Anthony Tennyson, CEO of Solvonis Therapeutics plc, added: "The grant of a
second U.S. patent within a week further strengthens the long-term value of
our PTSD programme and reinforces the depth of chemistry underpinning this
discovery programme. In an area of clear unmet need and rising strategic and
commercial interest, strong intellectual property matters. Securing patent
protection across multiple novel chemical series strengthens our position as
we advance SVN-114 and continue to expand our CNS pipeline."

 

 

Enquiries:

 

 Solvonis Therapeutics plc                                       Via Walbrook
 Anthony Tennyson, CEO & Executive Director

 Singer Capital Markets (Broker)                                 +44 (0) 20 7496 3000
 Phil Davies

 Walbrook PR (PR/IR advisers)  Tel: +44 (0)20 7933 8780 or solvonistherapeutics@walbrookpr.com
                               (mailto:solvonistherapeutics@walbrookpr.com)
 Anna Dunphy                                                     Mob: +44 (0)7876 741 001
 Lianne Applegarth                                               Mob: +44 (0)7584 391 303
 Rachel Broad                                                    Mob: +44 (0)7747 515 393

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company
developing small-molecule therapeutics for high-burden central nervous system
(CNS) disorders. Headquartered in London and listed on the main market of the
London Stock Exchange, Solvonis is advancing a differentiated pipeline of
repurposed and discovery-stage compounds across addiction and psychiatry.

 

The Company's lead programmes target Alcohol Use Disorder (AUD) and
Post-Traumatic Stress Disorder (PTSD), with additional development and
discovery work supporting expansion into further addiction and psychiatric
indications, including stimulant use disorder and depressive disorders.

 

Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK,
while SVN-002 is preparing for a Phase 2b trial in the United States targeting
moderate-to-severe AUD. The Company's PTSD discovery programme has identified
SVN-114 as a lead compound, emerging from a proprietary compound series
designed to modulate key brain signalling systems associated with emotional
processing and social behaviour.

 

In parallel, Solvonis is advancing proprietary CNS discovery programmes
supported by a dedicated compound library to identify new small-molecule
modulators of key neurotransmitter systems. This platform enables efficient
early-stage innovation and supports the Company's integrated approach to
developing therapies across addiction and psychiatry.

 

With a capital-efficient development model and a focus on partnering
opportunities, Solvonis aims to deliver sustained value through innovation in
CNS therapeutics.

 

solvonis.com (https://solvonis.com) | LinkedIn
(https://www.linkedin.com/company/solvonis) | X (Twitter)
(https://x.com/Solvonis)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEALLXEEXKEFA



            Copyright 2019 Regulatory News Service, all rights reserved